Project Grant R21CA317274
Award Date 9/3/26
Completion Date 8/31/28
Dollars Obligated $445K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $681,200 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer and test strategies to overcome that resistance. The project tests whether CD74-positive drug-tolerant persister cells drive acquired resistance to osimertinib and other third-generation EGFR tyrosine kinase inhibitors. The...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $524,110 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Assistance Listing Project Grant R01CA314254). The award funds research on one-ended break repair mechanisms in mammalian cells, specifically investigating how cells repair DNA damage at broken replication forks and double-strand...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $470,567 Project Grant (R21) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with an ultimate completion date of June 30, 2027. The award funds research to identify molecular features that predict response or resistance to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy in metastatic breast cancer patients...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $528,099 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize therapeutic vulnerabilities in ovarian clear cell carcinoma and develop new treatment strategies for both ARID1A-mutant and ARID1A-wildtype disease. The funded research identifies the PI3K/mTOR and HIF/VEGF pathways as fundamental therapeutic targets in ovarian clear cell carcinoma, with particular focus on synergy...
- The National Institutes of Health National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $463,279 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate USP1 inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer. The research will confirm the cytotoxic effects of the USP1 inhibitor RO7623066 in ovarian cancer cells and xenograft models harboring homologous recombination alterations, with particular focus on...
- The National Institutes of Health National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $628,394 on May 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a patient-derived organoid with tumor microenvironment (PDOT) co-culture system for modeling therapeutic responses in intrahepatic cholangiocarcinoma. The recipient will establish a precision preclinical platform that simultaneously reconstitutes intrahepatic cholangiocarcinoma...
- The National Cancer Institute awarded Oregon Health & Science University $356,850 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on targeting YB-1 to overcome chemoresistance in ovarian cancer. The project addresses treatment resistance in recurrent ovarian cancer by developing and evaluating a novel therapeutic approach to inhibit Y-box binding protein 1 (YB-1), a stress-responsive protein implicated in ovarian cancer progression and...
- The National Cancer Institute awarded The Methodist Hospital Research Institute $415,257 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop platinum-based nanotherapeutics for chemoresistant high-grade serous ovarian cancer. The award funds research into CARRIER-PT, a platinum nanoparticle therapy designed to overcome treatment resistance in ovarian cancer patients who fail conventional chemotherapy and immunotherapy. The work aims to determine how CARRIER-PT...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $621,121 on July 10, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tumor-niche co-evolution mechanisms driving ovarian cancer metastasis and therapeutic resistance. The research integrates clonal barcoding, single-cell RNA sequencing, and in vivo CRISPR screens to trace the evolutionary trajectory of metastatic ovarian cancer cells and define niche adaptive changes that...
- The National Institutes of Health National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $430,521 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop, optimize, and validate novel monoclonal antibody tools for exploring altered glycosylation in tumor cells. The recipient will develop and validate TACA-specific (tumor-associated carbohydrate antigen-specific) monoclonal antibodies targeting dysregulated glycan expression on cancer cell...